The CROCO (CROhn's Disease COhort Study) - study design and protocol
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00086164" target="_blank" >RIV/00023001:_____/25:00086164 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10502932
Result on the web
<a href="https://journals.sagepub.com/doi/epdf/10.1177/17562848251362594" target="_blank" >https://journals.sagepub.com/doi/epdf/10.1177/17562848251362594</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1177/17562848251362594" target="_blank" >10.1177/17562848251362594</a>
Alternative languages
Result language
angličtina
Original language name
The CROCO (CROhn's Disease COhort Study) - study design and protocol
Original language description
Background: Crohn's disease (CD) is a chronic, relapsing and remitting inflammatory bowel disease that can be associated with significant bowel damage and disability. The L & eacute;mann Index (LI) is a validated tool for measuring cumulative bowel damage in CD patients through a comprehensive assessment of stricturing, penetrating and surgical lesions. However, prospective studies evaluating bowel damage progression in recently diagnosed CD patients remain limited.Objectives: To characterise the absolute and longitudinal variations in bowel damage progression, as measured by the LI, in a cohort of recently diagnosed CD patients, and to assess its association with relevant disease features, including disease phenotype, treatment strategies, biomarkers and disability.Design: Study protocol for the Crohn's Disease Cohort Study (CROCO Study), a multicentre, European, prospective cohort study.Methods and analysis: Patients with recently diagnosed CD (within the previous 12 months) will be enrolled and followed up for 5 years. Patients will receive standard-of-care treatment determined by the practising gastroenterologist. Morphological assessments to measure the LI and to evaluate bowel damage progression will be performed at years 1, 3 and 5 after the diagnosis. Disability will be assessed annually using the Inflammatory Bowel Disease - Disability Index (IBD-DI). The primary outcome will be the absolute LI at year 3 following diagnosis. Predictors of bowel damage progression and the association between bowel damage and disability will be analysed.Discussion: The CROCO study represents a unique multicentre cohort of recently diagnosed CD patients, designed to advance the understanding of CD's natural history and evolution. It will facilitate the development of composite scores for predicting bowel damage progression and provide valuable tools for designing future disease-modification trials.Trial registration: NCT05420233.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Therapeutic advances in gastroenterology
ISSN
1756-283X
e-ISSN
1756-2848
Volume of the periodical
18
Issue of the periodical within the volume
July 2025
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
"art. no. 17562848251362594"
UT code for WoS article
001563525900001
EID of the result in the Scopus database
2-s2.0-105024561007